KR102575788B1 - 개선된 fviii 융합 단백질 및 이의 용도 - Google Patents

개선된 fviii 융합 단백질 및 이의 용도 Download PDF

Info

Publication number
KR102575788B1
KR102575788B1 KR1020207034852A KR20207034852A KR102575788B1 KR 102575788 B1 KR102575788 B1 KR 102575788B1 KR 1020207034852 A KR1020207034852 A KR 1020207034852A KR 20207034852 A KR20207034852 A KR 20207034852A KR 102575788 B1 KR102575788 B1 KR 102575788B1
Authority
KR
South Korea
Prior art keywords
ser
leu
gly
pro
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207034852A
Other languages
English (en)
Korean (ko)
Other versions
KR20210005248A (ko
Inventor
홍성 수
시아오산 왕
빈 리우
시안 천
시앙 리
루얀 주
쉬야 왕
쉬앙 왕
원원 왕
링리 후앙
치레이 왕
하이타오 후
리리 장
지에 가오
즈지아 런
춘펑 시아오
얄리 왕
Original Assignee
정저우 젠사이언시스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 정저우 젠사이언시스 인코포레이티드 filed Critical 정저우 젠사이언시스 인코포레이티드
Publication of KR20210005248A publication Critical patent/KR20210005248A/ko
Application granted granted Critical
Publication of KR102575788B1 publication Critical patent/KR102575788B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020207034852A 2018-05-18 2019-05-16 개선된 fviii 융합 단백질 및 이의 용도 Active KR102575788B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810481941 2018-05-18
CN201810481941.X 2018-05-18
PCT/CN2019/087156 WO2019219049A1 (zh) 2018-05-18 2019-05-16 改进的fviii融合蛋白及其应用

Publications (2)

Publication Number Publication Date
KR20210005248A KR20210005248A (ko) 2021-01-13
KR102575788B1 true KR102575788B1 (ko) 2023-09-08

Family

ID=68539524

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207034852A Active KR102575788B1 (ko) 2018-05-18 2019-05-16 개선된 fviii 융합 단백질 및 이의 용도

Country Status (9)

Country Link
US (1) US12440572B2 (enExample)
EP (1) EP3816181A4 (enExample)
JP (2) JP2021530437A (enExample)
KR (1) KR102575788B1 (enExample)
CN (2) CN117467019A (enExample)
BR (1) BR112020023168A2 (enExample)
MA (1) MA53020A (enExample)
MX (1) MX2020012103A (enExample)
WO (1) WO2019219049A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117337307A (zh) * 2022-05-25 2024-01-02 江苏晟斯生物制药有限公司 具有延长的半衰期的fviii融合蛋白缀合物及其应用
CN116284411B (zh) * 2023-02-03 2024-02-13 北京基科晟斯医药科技有限公司 抗培重组人凝血因子VIII-Fc融合蛋白的抗体及其应用
CN116036244B (zh) * 2023-02-24 2023-09-19 北京基科晟斯医药科技有限公司 培重组人凝血因子VIII-Fc融合蛋白用于治疗含抑制物的血友病A的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011101284A1 (en) * 2010-02-16 2011-08-25 Novo Nordisk A/S Factor viii fusion protein
WO2013106787A1 (en) 2012-01-12 2013-07-18 Biogen Idec Ma Inc. Chimeric factor viii polypeptides and uses thereof
CN106279437A (zh) * 2016-08-19 2017-01-04 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
WO2017117631A1 (en) 2016-01-07 2017-07-13 Csl Limited Mutated truncated von willebrand factor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818679A (en) 1985-02-19 1989-04-04 The Trustees Of Columbia University In The City Of New York Method for recovering mutant cells
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
AU8576298A (en) 1997-07-18 1999-02-10 Chiron Corporation Lentiviral vectors
ES2633916T3 (es) 2004-11-12 2017-09-26 Bayer Healthcare Llc Modificación de FVIII dirigida al sitio
US20080255026A1 (en) 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US20120121613A1 (en) 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety
JP5914363B2 (ja) 2010-02-16 2016-05-11 ノヴォ ノルディスク アー／エス 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
EP2768853A1 (en) 2011-10-18 2014-08-27 CSL Limited Method for improving the stability of purified factor viii after reconstitution
CN103172745A (zh) 2011-12-21 2013-06-26 北京韩美药品有限公司 包含免疫球蛋白Fc片段的长效人内皮抑素
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
WO2014026954A1 (en) 2012-08-13 2014-02-20 Novo Nordisk A/S Liquid factor viii formulations
WO2014100913A1 (en) 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
CN103539860B (zh) 2013-11-01 2014-12-03 广州优联康医药科技有限公司 一种长效重组人促卵泡激素融合蛋白
WO2017222337A1 (ko) * 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011101284A1 (en) * 2010-02-16 2011-08-25 Novo Nordisk A/S Factor viii fusion protein
WO2013106787A1 (en) 2012-01-12 2013-07-18 Biogen Idec Ma Inc. Chimeric factor viii polypeptides and uses thereof
WO2017117631A1 (en) 2016-01-07 2017-07-13 Csl Limited Mutated truncated von willebrand factor
CN106279437A (zh) * 2016-08-19 2017-01-04 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途

Also Published As

Publication number Publication date
US12440572B2 (en) 2025-10-14
KR20210005248A (ko) 2021-01-13
BR112020023168A2 (pt) 2021-02-09
JP7492780B2 (ja) 2024-05-30
JP2021530437A (ja) 2021-11-11
EP3816181A1 (en) 2021-05-05
EP3816181A4 (en) 2022-04-20
JP2023093634A (ja) 2023-07-04
CN113039200A (zh) 2021-06-25
CN113039200B (zh) 2023-07-25
CN117467019A (zh) 2024-01-30
US20210361775A1 (en) 2021-11-25
MA53020A (fr) 2021-05-05
WO2019219049A1 (zh) 2019-11-21
MX2020012103A (es) 2021-01-29

Similar Documents

Publication Publication Date Title
US11510968B2 (en) Method for improving the stability of purified Factor VIII after reconstitution
JP7492780B2 (ja) 改良されたｆｖｉｉｉ融合タンパク質及びその応用
HUE033776T2 (en) FVIII site-specific modification
KR20150144803A (ko) 복합체
CN113166271A (zh) 具有延长半衰期的融合多肽缀合物
KR20140083036A (ko) 인자 ｖｉｉｉ의 생체이용률을 향상시키기 위한 황산화 글리코사미노글리칸의 용도
RU2789085C2 (ru) Улучшенный белок слияния fviii и его применение
HK40046100A (en) Improved fviii fusion protein and use thereof
EP4534563A1 (en) Fviii fusion protein conjugate having extended half-life and use thereof
HK40079628A (en) Subcutaneous administration of factor viii
CN114929261A (zh) 凝血因子viii的皮下施用
TW202540157A (zh) 具有延長的半衰期的ｆｖｉｉｉ融合蛋白綴合物及其應用

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20201203

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201203

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230130

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230808

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230904

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230905

End annual number: 3

Start annual number: 1

PG1601 Publication of registration